abstract |
The present technology aims to provide novel drugs for the treatment of subjects suffering from autoimmune or inflammatory diseases. In particular, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs) characterized in that at least two ISVDs bind TNFα and At least two ISVDs bind to OX40L. The present technology also provides nucleic acids, vectors and compositions. |